David Denning

David Denning is an infectious diseases clinician with expertise in fungal diseases.  He trained at Guys Hospital, London and as a young doctor also in London (University College and Northwick Park hospitals), Glasgow and Stanford, California. He has been researching, and caring for patients with aspergillosis since 1985, and has retired from clinical practice in 2020. He has published more than 600 papers and book chapters. He has successfully lead many major international collaborative science, diagnostic and treatment projects and clinical guidelines, with subsequent publication in Nature, the New England Journal of Medicine and the Lancet. He is heavily involved in postgraduate teaching and lectures worldwide. He was instrumental in the establishment of the Mycology Reference Centre in Manchester (2009), which grew out of the Fungal Testing Laboratory he founded in 1991. He was the founding Director of the UK’s National Aspergillosis Centre in 2009. His work has been cited over 75,000 times (Google scholar H-index 119). He is the Founder of 2 University spinout biotechnology companies – F2G Ltd and Myconostica Ltd. He chairs the Editorial Board of The Aspergillus Website (1998-) (www.aspergillus.org.uk) which attracts 70,000-100,000 visitors monthly. He leads LIFE (Leading International Fungal Education) (www.LIFE-Worldwide.org) and is President of the Global Action Fund for Fungal Infections (www.GAFFI.org). He co-chairs the alternate year Advances Against Aspergillosis meetings. He is a member of the SEARO Task Force on AMR.
Link: https://www.research.manchester.ac.uk/portal/en/researchers/david-denning(3472e155-0e6f-4a65-94b9-aa948795c9f6).html